Our thinking about milestone awards has changed.
Since we want the prize to be more open-ended, with teams possibly registering one or several years into the competition, teams won’t be progressing at a similar pace.
Instead, we’re thinking of milestone awards for teams that are the first to get their clinical trials approved in a certain category.
For example: gene therapy, or epigenetic reprogramming, or stem cells, or repurposed drugs.
An additional benefit would be that each milestone award could be funded by a different sponsor. A company that has an interest in gene therapy could sponsor a, say, $1 million gene-therapy milestone award. An individual with a particular interest in epigenetic reprogramming could sponsor a $500,000 milestone award in that category.
Our questions for you:
- Which categories should we consider?
- Could milestone awards in different categories differ? We ideally want to incentivize audacious treatments, so a milestone award for, say, gene therapy might be higher than one for repurposed drugs. (This would, of course, also depend on how much money sponsors are willing to put it.)
Other thoughts are welcome too! @goya, @markjayct, @pscheck, @danbelsky, @mario_perez, @Umbertog, @amoskalev, @Wally, please let us know what you think!